MiNK Therapeutics Inc Dossier - Source-backed chat

MiNK Therapeutics Inc

INKTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.65

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $12.73Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $65M

Enterprise Value $56.2M

Shares Outstanding 5.2M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MiNK Therapeutics is a clinical-stage biopharmaceutical pioneer developing off-the-shelf, allogeneic invariant natural killer T (iNKT) cell therapies. Its lead asset, agenT-797, has demonstrated unique context-dependent immune modulation, driving TH1 pro-inflammatory responses in solid tumors and TH2 anti-inflammatory responses in acute respiratory distress syndrome (ARDS). With a randomized Phase 2 trial actively dosing patients in acute lung injury and initial data expected in H2 2026, MiNK offers a high-upside opportunity in the cell therapy space. While the company faces typical early-stage biotech risks, including a limited cash runway and going concern disclosures, its vertically integrated manufacturing and non-dilutive partnership momentum provide a solid foundation for clinical validation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$35.00

Mean target$39.00

High · most bullish analyst$43.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0020%

Phase 2 clinical trials for agenT-797 encounter safety signals or fail to show clear efficacy differentiation over standard of care. Capital constraints intensify as cash reserves dwindle, forcing highly dilutive equity financing or a halt to early-stage programs like MiNK-215 and MiNK-413.

Base CaseCentral scenario

$35.0055%

Initial Phase 2 data for agenT-797 in ARDS/acute lung injury shows positive safety and encouraging efficacy trends in H2 2026, validating the platform's therapeutic potential. The company successfully extends its cash runway into 2027 through disciplined spending, ATM utilization, and selective regional collaborations, keeping clinical development on track.

Bull CaseUpside scenario

$43.0025%

The randomized Phase 2 trial of agenT-797 in acute lung injury delivers outstanding efficacy and safety data in H2 2026, establishing iNKT cells as a breakthrough class of immune reconstitution therapies. This triggers a lucrative global co-development partnership, fully funding the pipeline and resolving going concern risks. Concurrently, preclinical asset MiNK-215 successfully enters the clinic, driving the stock toward the high analyst target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pioneering platform in allogeneic, off-the-shelf iNKT cell therapies, which naturally home to tissues and avoid the need for HLA matching or lymphodepletion.
Lead candidate agenT-797 has treated approximately 100 patients, demonstrating a favorable safety profile and context-dependent immune restoration across oncology and pulmonary diseases.
Active randomized Phase 2 trial in acute lung injury and critical illness with key clinical readouts anticipated in the second half of 2026.
Vertically integrated manufacturing capabilities that support scalable, reproducible, and cost-effective cell therapy production.

Key Investment Risks

Limited cash runway of approximately $9.5 million as of Q1 2026, with management expressing substantial doubt about the company's ability to continue as a going concern without additional funding.
High dependency on a single lead asset (agenT-797), making the company's valuation highly sensitive to clinical trial outcomes.
Intense competition in the allogeneic cell therapy landscape from established NK and CAR-T platforms.

Thesis Invalidation Triggers

Failure of agenT-797 to meet primary safety or efficacy endpoints in the ongoing randomized Phase 2 trial for acute lung injury.
Inability to secure additional financing or strategic partnerships before early 2027, leading to severe operational curtailment.
Severe regulatory delays or clinical holds imposed by the FDA on the iNKT platform.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.